Innoviva, Inc. Common Stock
Veridion Score
Composite trend over time
Why is INVA moving today?
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for INVA.
INVA insider activity
Innoviva, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $2.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-20 | Basso Stephen | Insider | sell | $22.24 | 559 | 88,571 | $12K | SEC Form 4 |
| 2026-05-22 | 2026-05-20 | Raifeld Pavel | Insider | sell | $22.24 | 1,130 | 285,929 | $25K | SEC Form 4 |
| 2026-05-22 | 2026-05-20 | Zhen Marianne | Insider | sell | $22.24 | 1,127 | 57,516 | $25K | SEC Form 4 |
| 2026-02-24 | 2026-02-20 | Basso Stephen | Insider | sell | $23.39 | 1,244 | 50,013 | $29K | SEC Form 4 |
| 2026-02-24 | 2026-02-20 | Raifeld Pavel | Insider | sell | $23.39 | 2,986 | 159,290 | $70K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 7 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moINVA contract awards, year to date.
Public federal awards linked to this ticker.
INVA lobbying filings, year to date.
Registered lobbying filings matched to Innoviva, Inc. Common Stock.